甲磺酸倍他司汀辅助治疗前庭性偏头痛的效果

Effect of Betahistine Mesylate in Adjuvant Treatment of Vestibular Migraine

目的:探究甲磺酸倍他司丁辅助治疗前庭性偏头痛的效果及对脑血流速度、血清神经递质水平及眩晕症状的影响。方法:选取我科2020年9月—2022年9月收治的87例前庭性偏头痛患者作为研究对象,采用随机数字表法分为对照组(43例)和观察组(44例)。对照组给予口服盐酸氟桂利嗪胶囊治疗,观察组在对照组基础上联合甲磺酸倍他司丁治疗,比较两组临床疗效、眩晕情况、血清神经递质水平[降钙素基因相关肽(CGRP)、内皮素-1(ET-1)及P物质(SP)]、脑血流速度[基底动脉(BA)、大脑中动脉(MCA)、大脑后动脉(PCA)、大脑前动脉(ACA)]及不良反应。结果:观察组CGRP、SP、ET-1水平低于对照组(P<0.05);观察组MCA、ACA、PCA及BA指数低于对照组(P<0.05);观察组眩晕累计发作时间、眩晕累计发作次数及眩晕发作强度均低于对照组(P<0.05);观察组治疗总有效率为90.91%,高于对照组的72.09%(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:加用甲磺酸倍他司丁辅助治疗VM患者的疗效确切,可明显降低患者血清神经递质水平,改善脑血流循环,调节脑血流速度,改善眩晕症状,且不良反应少。

Objective:To explore the effect of betahistine mesylate in adjuvant treatment of vestibular migraine and its effect on cerebral blood flow velocity,serum neurotransmitter level and vertigo symptoms.Methods:A total of 87 patients with vestibular migraine admitted to our department from September 2020 to September 2022 were selected as the research objects.They were divided into control group(43 cases)and observation group(44 cases)by random number table method.The control group was treated with oral flunarizine hydrochloride capsules,and the observation group was treated with betahistine mesylate on the basis of the control group.The clinical efficacy,vertigo,serum neurotransmitter levels[calcitonin gene-related peptide(CGRP),endothelin-1(ET-1)and substance P(SP)],cerebral blood flow velocity[basilar artery(BA),middle cerebral artery(MCA),posterior cerebral artery(PCA),anterior cerebral artery(ACA)]and adverse reactions were compared between the two groups.Results:The levels of CGRP,SP and ET-1 in the observation group were lower than those in the control group(P<0.05).The indexes of MCA,ACA,PCA and BA in the observation group were lower than those in the control group(P<0.05).The cumulative attack time,cumulative attack frequency and intensity of vertigo in the observation group were lower than those in the control group(P<0.05).The total effective rate of treatment in the observation group was 90.91%,which was higher than 72.09% in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:Betahistine mesylate is effective in the adjuvant treatment of VM patients,which can significantly reduce the level of serum neurotransmitters,improve cerebral blood flow circulation,regulate cerebral blood flow velocity,improve vertigo symptoms,and have fewer adverse reactions.